Overview and Scope
G-CSF (granulocyte colony stimulating factors) market refers to a type of colony-stimulating factor that aids in the bone marrow’s ability to produce more white blood cells. Patients who have specific tumors, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it.
Sizing and Forecast
The g-csf (granulocyte colony stimulating factors) market size has grown steadily in recent years. It will grow from $8.84 billion in 2023 to $9.17 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to increase in cancer prevalence, strong economic growth in emerging markets, increased healthcare expenditure, increase in pharmaceutical r&d expenditure and government initiatives.
The g-csf (granulocyte colony stimulating factors) market size is expected to see steady growth in the next few years. It will grow to $10.98 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to increasing prevalence of cancer, increasing demand for prophylaxis granulocyte colony-stimulating factor (g-csf), rise in healthcare expenditure, high potential of emerging economies, technology advances and high penetration of the biosimilar drugs. Major trends in the forecast period include investing extensively in r&d activities for the development of effective and innovative drugs, increasing focus on m&a growth strategies to expand the customer base and geographic markets, establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and focusing efforts towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report
Segmentation & Regional Insights
The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –
1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product: Tablet, Capsule, Other Products
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications
North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2023. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (granulocyte colony stimulating factor) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in 2023 in the United States. G-CSF (granulocyte colony stimulating factor) is a class of growth factors that produce white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infections after certain forms of cancer treatment. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF (granulocyte colony stimulating factor) market.
Key Industry Players
Major companies operating in the g-csf (granulocyte colony stimulating factors) market report are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd, BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy’s Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratórios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline plc, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.
The g-csf (granulocyte colony stimulating factors) market report table of contents includes:
1. Executive Summary
2. G-CSF (Granulocyte Colony Stimulating Factors) Market Characteristics
3. G-CSF (Granulocyte Colony Stimulating Factors) Market Trends And Strategies
4. G-CSF (Granulocyte Colony Stimulating Factors) Market – Macro Economic Scenario
5. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Size and Growth
…
32. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Benchmarking
33. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Dashboard
34. Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimulating Factors) Market
35. G-CSF (Granulocyte Colony Stimulating Factors) Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
